Please assess the completion status of the following clinical trial:

Trial Title: S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histopathologically confirmed extrahepatic cholangiocarcinoma of the gallbladder or bile duct, meeting at least 1 of the following criteria:~  * Pathological T2-4 disease~ * Pathological N1 disease~ * Positive margins (any T or N )~* Must have undergone potentially curative radical resection with negative (R0) or microscopically positive (R1) margins within the past 56 days and recovered (R0 stratum closed as of 12-15-11)~* No distant metastatic disease as indicated by a CT scan or MRI of the chest, abdomen, and pelvis within the past 42 days~  * Positive resected regional lymph nodes allowed~* No ampullary cancer~PATIENT CHARACTERISTICS:~* Zubrod performance status 0-1~* ANC \> 1,500/μL~* Platelet count \> 100,000/μL~* Serum creatinine \< 1.5 mg/dL~* Total bilirubin \< 1.5 times upper limit of normal (ULN)~* SGOT or SGPT \< 2.5 times ULN~* Not pregnant or nursing~* Fertile patients must use effective contraception~* Able to swallow enteral medications and no requirement for a feeding tube~* No intractable nausea or vomiting~* No gastrointestinal (GI) tract disease resulting in an inability to take oral medication, malabsorption syndrome, requirement for IV alimentation, prior surgical procedures affecting absorptions. or uncontrolled inflammatory GI disease (e.g., Crohn disease, ulcerative colitis)~* No uncontrolled intercurrent illness including but not limited to any of the following:~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Myocardial infarction or cerebrovascular accident within the past 3 months~ * Uncontrolled diarrhea~ * Psychiatric illness or social situations that would limit compliance with study requirements~* No prior malignancy except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer, or other cancer from which the patient has been disease-free for 5 years~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior chemotherapy or radiotherapy for this disease~* No prior upper abdominal radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Adjuvant Chemo+ Chemoradiotherapy (Type: EXPERIMENTAL): Adjuvant Chemotherapy~* Capecitabine, 1500 mg/m\^2/day, PO, Every 12 hrs on Days 1-14 of each cycle~* Gemcitabine hydrochloride, 1000 mg/m\^2, IV, Days 1 \& 8 of each cycle~Chemoradiotherapy~-Capecitabine, 1330 mg/m\^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT~Radiation (RT):~3-dimensional conformal radiation therapy - 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.~intensity-modulated radiation therapy: 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.

Based on this trial design, predict the completion outcome and termination type (if applicable).